Recently Van Den Bosch and colleagues have shown that the oral treatment of the ALS transgenic mouse model Tg FUS+/+ (both males and females) with ACY-738 (100 mg/kg) slowed down the disease progression, and improved the lifespan (Rossaert et al., 2019). Here, FUS is linked to amyotrophic lateral sclerosis.